Company: REVB
Filing Date: 2025-05-23
Form Type: S-1/A
Source: 0001213900-25-047104
Chunk: 107

Company: REVELATION BIOSCIENCES, INC.
Filing Date: 2025-05-23
Form: S-1/A
Chunk 107
---
 significantly reduced duration and severity of infection following bacterial challenge with either gram-positive or gram-negative bacteria as indicated in the following figures. Pretreatment with PHAD Impart Protection from Gram Negative Bacterial Infection 67 Pretreatment with PHADs Impart Protection from Gram Positive Bacterial Infection Clinical Development Plan During 2024 we conducted a Phase 1 clinical study. Subsequently, safety and biomarker activity data from our Phase 1 clinical study was announced in June of 2024, showing a significant increase in anti-inflammatory cytokines including IL-1RA and IL-10. We are evaluating the next steps to be taken in the development of Gemini-PSI. Gemini-PBI Program Overview The Gemini-PBI program is being developed, through a license agreement with Vanderbilt University, as a potential therapy for the prevention of infection in severe burn patients requiring hospitalization. We believe Gemini administration to severe burn patients will augment the patient’s immune response to resist infection by activating the body’s immune system to better and more rapidly respond to pathogen exposure. Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD-like molecules) post-burn results in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Preclinical studies Preclinical studies in a burn model have shown that systemic administration of MPLA (a bacterially derived mixture of PHAD-like molecules) post-burn results in a significantly augmented immune response leading to significantly reduced duration and severity of infection following pseudomonas challenge. Figure 13: Reduced Plasma Lactate, Reduced Msofa Score, and Reduced Lung P. Aeruginosa Counts in Response to Pre-Treatment With MPLA in a Sheep Burn Model. (Fukuda 2020) 68 Sheep underwent 20% TBSA cutaneous burn at time 0 followed by vehicle or MPLA (2.5 μg/kg) infusion at 24 hours after burn injury. P. aeruginosawas instilled into the lungs at 48 hours after burn injury The figure shows numbers of the bacteria in lung culture (at 24 hours after P. aeruginosainfection). Open circles represent MPLA preconditioned treatment group animals. Closed circles represent control group. The animal numbers are n=6. Data are expressed as mean ± SEM (* p < 0.05 vs. control). Panel A shows significantly lower plasma lactate concentration in treated vs untreated animals. Panel B shows significantly improved